Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vicky Makker

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 21, 2026
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomesChristian Marth, Domenica Lorusso, Mariusz Bidziński, et al.
Gynecologic Oncology|June 4, 2024
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO studyVicky Makker, Jose Alejandro Perez-Fidalgo, Giorgio Valabrega, et al.
Nature Medicine|April 23, 2024
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analysesClaire F Friedman, Beryl L Manning-Geist, Qin Zhou, et al.
Journal for Immunotherapy of Cancer|February 19, 2026
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775Vicky Makker, Nicoletta Colombo, Antonio Casado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2021
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II StudyOliver Zivanovic, Dennis S Chi, Qin Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2018
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial CancerTara E Soumerai, Mark T A Donoghue, Chaitanya Bandlamudi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 30, 2022
Endometrial carcinosarcomaGiorgio Bogani, Isabelle Ray-Coquard, Nicole Concin, et al.
Journal of the National Cancer Institute|February 6, 2023
Comprehensive analysis of germline drivers in endometrial cancerSushmita Gordhandas, Eric Rios-Doria, Karen A Cadoo, et al.
Nature Communications|May 26, 2026
Very low-carbohydrate ketogenic diet in treatment-naïve women with endometrial cancer and overweight: a randomized feasibility studyEzequiel Dantas, Katie C Hootman, Jenna Moyer, et al.
Cancer Discovery|March 28, 2020
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung CancersBob T Li, Flavia Michelini, Sandra Misale, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 21, 2026
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomesChristian Marth, Domenica Lorusso, Mariusz Bidziński, et al.
Gynecologic Oncology|June 4, 2024
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO studyVicky Makker, Jose Alejandro Perez-Fidalgo, Giorgio Valabrega, et al.
Nature Medicine|April 23, 2024
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analysesClaire F Friedman, Beryl L Manning-Geist, Qin Zhou, et al.
Journal for Immunotherapy of Cancer|February 19, 2026
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775Vicky Makker, Nicoletta Colombo, Antonio Casado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2021
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II StudyOliver Zivanovic, Dennis S Chi, Qin Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2018
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial CancerTara E Soumerai, Mark T A Donoghue, Chaitanya Bandlamudi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 30, 2022
Endometrial carcinosarcomaGiorgio Bogani, Isabelle Ray-Coquard, Nicole Concin, et al.
Journal of the National Cancer Institute|February 6, 2023
Comprehensive analysis of germline drivers in endometrial cancerSushmita Gordhandas, Eric Rios-Doria, Karen A Cadoo, et al.
Nature Communications|May 26, 2026
Very low-carbohydrate ketogenic diet in treatment-naïve women with endometrial cancer and overweight: a randomized feasibility studyEzequiel Dantas, Katie C Hootman, Jenna Moyer, et al.
Cancer Discovery|March 28, 2020
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung CancersBob T Li, Flavia Michelini, Sandra Misale, et al.
Pageof 14